Principal Investigator/Program Director: Meyskens, Frank L. 5P30CA062203-17
BIOGRAPHICAL SKETCHProvide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
Mercola, Dan / POSITION TITLE
Professor of Pathology and Laboratory Medicine
eRA COMMONS USER NAME (credential, e.g., agency login)
DanMercola
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)
INSTITUTION AND LOCATION / DEGREE
(if applicable) / MM/YY / FIELD OF STUDY
University of California, Los Angeles / BA / 06/63 / Psychology
University of California, Los Angeles, / MS / 06/67 / Biophysics
University of California, Los Angeles, / PhD / 06/69 / Biophysics
University of Southampton, England / BM / 12/81 / Medicine
A. Personal Statement
I am a Professor of Pathology and direct the Laboratory of Translational Cancer Biology and am P.I. for the NCI UCI EDRN (Early Detection Research Network) UO1 consortium of which UCI is a designated “Biomarker Discovery Laboratory”. Within the Chao Family Comprehensive Cancer Center I am Co-Leader of the Cancer Prevention and Surveillance Program with Dr. Christine McLaren and am a member of the Senior Leadership Council.
B. Positions and Honors
Positions and Employment
1969-1973 University of Oxford, postdoctoral fellow with Prof. Dorothy Hodgkin (Nobel Laureate)
1974-1979 University of Oxford, Member of Faculty of Agricult. & Biol. Sci., (M.A., 1974) and Wolfson College
1982- California State Medical License, M.D., No. A 40362; DEA No. BM3561467
1981-1985 Resident, Pathology, University of California at San Diego, Board Certification: 1985; F.C.A.P
1985-1991 Assistant Clinical Professor, University of California at San Diego, Pathology Department
1985-1995 Associate Adjunct Professor, University of California at San Diego, Pathology Department
1985-1997 Staff Physician, DVAMC, San Diego, CA
1993-2005 Professor, Sidney Kimmel Cancer Center, University of California, San Diego, San Diego, CA
2005- Professor, Pathology & Laboratory Medicine, University of California, Irvine, Irvine, CA
2005- Director, Translational Cancer Biology, University of California, Irvine, Irvine, CA
Other Experience and Professional Memberships
1995- Member, NIH Site Visit Review Committee, Program Project Grant Application
1992- Editorial Boards: Antisense and Nucleic Acid Drug Development; Cancer Gene Therapy
1992-1997 Member, Organizing Committee of the Am. Assoc. Clin. Chem. Annual San Diego Conference
1993- NIH Ad Hoc Reviewer, Study Section, RFA: "Cancer Therapy with Biological Response Modifiers"
1993- 1998 Member, Grants Review subcommittee for Oncology, 9/93-10/99, U.S. Dept. of Veterans Affairs
1999- Associate Member, UCSD Cancer Center
2004 NIH Study Section member, ZCA1, June 7-8, 2004, Dr. T. Meeker, SRA.
2004 NIH site visit to NIH Cancer and Cell Biology Branch, Sept. 21-23, 2004, M. Johnson, Exec. Sec.
2004-2006 NIH, member, Research Evaluation Panel, the NCI CPCTR, Canc. Diag. Prog.
2004-2005 NIH study section, 'EDRN: Biomarkers Development Laboratory', Review panel.
2005 NIH Study Section member, ZCA1 SRRB-E, CMCAR, 6/20/05, Tim Meeker, SRA.
2006 Department of Defense, Breast Cancer, Study Section.
2008 Department of Defense, Prostate Cancer, Study Section, Panel for Molecular Biology
2009 Department of Defense, Breast Cancer Grants Review Panel, CBY-1, B. DiVenney, SRA.
2010-2011 SWOG SELECT / PCPT biorepository Study Section, annual, F. Meyskens, organizer.
2011-2014 Study Section, NCI, Cancer Diagnosis Program, Special Emphasis Panel, Clinical Assay Development, Barbara Conley, Associate Director.
Honors
1972 Science Citation Classic, Blundell et al, Insulin, its structure, biology, and activity. The Proteins
1974 Oxford University, matriculated as M.A. status
2004 San Diego Padres Medical All-Star for 2004 presented by M. Milkin
C. Selected peer-reviewed publications (Selected from 130)
1. Jun Hayakawa, Shalu Mittal, Yipeng Wang, Kemal Korkmaz, Mashide Ohmichi, Eileen Adamson, Michael McClelland, Dan Mercola. Identification of genes bound and regulated by ATF2/c-Jun following genotoxic stress. Molecular Cell 2004;16:521-535. PMID 15546613.
2. Anja Krones-Herzig, Shalu Mittal, Kelly Yule, Hongyan Liang, Chris English, Rafael Urcis, Tarun Soni, Eileen D. Adamson, and Dan Mercola. Egr1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Research. 2005;65(12):5133-43. PMID 15958557.
3. Maryla Krajewska, Alan H.Olson, Dan Mercola, John C. Reed JC, Stan Krajewski. Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate. Prostate. 2007 Jun 15;67(9):907-10. PMID 17440968.
4. Krajewska, M., Kitada, S., Winter, J. N., Variakojis, D., Lichtenstein, A., Zhai, D., Cuddy, M., Huang, X., Luciano, F., Baker, C. H., Kim, H., Shin, E., Kennedy, S., Olson, A. H., Badzio, A., Jassem, J., Meinhold-Heerlein, I., Duffy, M. J., Schimmer, A. D., Tsao3, M., Brown, E, Sawyers, A., Andreeff1, M., Mercola, D., Krajewski, S. & Reed, J.C. (2008). Bcl-B Expression in Human Epithelial & Nonepithelial Malignancies Clin.Canc.Res., 14:3011-3021. PMID 18483366
5. Yu, J., Zhang, S.S., Saito, K., Williams, S., Arimura, Y., Ma, Y., Ke, Y., Baron, V., Mercola, D., Feng, G.S., Adamson, E., Mustelin, T. (2009). PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J., 7;28(1):21-33. Epub 2008 Dec. PMID 19057511. PMCID 2633077
6. Koziol, J.A., Feng, A.C., Jia, Z., Wang, Y., McClelland, M., Mercola, D. (2008). The Wisdom of the Commons: Ensemble Tree Classifiers for Prostate Cancer Prognosis. Bioinformatics, 25:54-60. PMID 18628288. PMCID 2638928
7. Arora, S., Wang, Y., Jia, Z., Vardar-Sengul, S., Munawar, A., Doctor, K.S., Birrer, M., McClelland, M., Adamson, E., Mercola, D. (2008). Egr1 Regulates the Coordinated Expression of Numerous EGF Receptor Target Genes as identified by ChIP on chip of Prostate Cancer Cells. Genome Biology, 9:R166 (Epub ahead of publication). PMID 19032775.
8. Hewitt, R., Watson, P.H., Dhir, R., Aamodt, R., Thomas, G., Mercola, D., Grizzle, W.E., Morente, M. (2009 Jan 1). Timing of consent for the research use of surgically removed tissue: is Postoperative Consenting Acceptable? Cancer, 115(1):4-9. PMID 19090013.
9. Vardar-Sengul, S., Arora, S., Baylas, H., & Mercola, D. (2009). Expression profile of human gingival fibroblasts induced by interleukin-1b reveals central role of NFkB in stabilizing human gingival fibroblasts during inflammation. J. Peridontal Res., 2009;80(5):833-49. PMID 19405838.
10. Jia, Z., Wang, Y., Ye, K., Li, Q., Tang, S., Xu, S., Mercola, D. (2009). Association study between gene expression and multiple relevant phenotypes with cluster analysis. Lect Notes Comput Sci., 5483:1-12. PMID 19655036. PMCID 2719899.
11. Tang, Y., Simoneau, A.R., Liao, W.X., Yi, G., Hope, C., Liu, F., Li, S., Xie, J., Holcombe, R.F., Jurnak, F.A., Mercola, D., Hoang, B.H., Zi, X. (2009). WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest & growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Ther, 8:458-68. PMID 19174556. PMCID 2768341.
12. Wang, Y., Xia, X-Q., Jia, Z., Sawyers, A., Yao, H., Wang-Rodriquez, J., McClelland, M., Mercola*, D. (2010). In silico estimates of tissue components in surgical samples based on expression profiling data. Cancer Research, 70:6448-55. PMID: 20663908 *these two authors contributed equally. PMID 20663908
13. Jia, Z., Wang, Y., Sawyers, A., Yao2, H., Rahmatpanah, F., Xia, X-Q., Xu, Q., Pio Tolga Turan, R., Koziol, J.A., Goodison, S., Carpenter, P., Wang-Rodriquez, J., Simoneau, A., Meyskens, F., Sutton, M., Lernhardt, W., Beach, T., Monforte, J., McClelland, M. and Mercola, D. (2011). Diagnosis of Prostate Cancer Using Differentially Expressed Genes in Stroma. Cancer Research, 71(7):2476-2487. PMID 21459804. *Contributed equally.
14. Major JM, Klonoff-Cohen HS, Pierce JP, Slymen DJ, Saltzstein SL, Macera, C., Mercola, Dan, Kattan M.W.. Prostate Cancer Postoperative Nomogram Scores and Obesity. PLoS ONE. 2011;6(2):e17382. doi:10.1371/journal.pone.0017382. PMID 21390220. PMCID 3044730.
15. Xin, Chen, Shizhong Xu, Yipeng Wang, Michael McClelland, Zhenyu Jia, and Dan Mercola. Identification of Biomarkers for Prostate Cancer Prognosis Using a Novel Two-Step Cluster Analysis, in M. Loog et al. (Eds.): PRIB 2011, LNBI 7036, pp. 63–74, 2011. Springer-Verlag Berlin Heidelberg 2011.
D. Research Support
Ongoing Research Support
5P30CA062203-16 Meyskens (PI) 02/01/09-01/31/14
NIH/NCI
University of California Irvine Cancer Center Support Grant Infrastructure and Research award to support cancer research at UC Irvine and beyond
Role: Co-leader for the Prostate Translational Working Group
1U01CA152738-01 (Mercola) 09/01/10-06/30/15
NIH/NCI
The Prostate Cancer Tumor Microenvironment Exhibits Differentially Expressed Genes Useful for Diagnosis
The establishment of UCI as a “Biomarker Dectecion Laboratory” for the NCI EDRN and to develop a multisite prospective clinical validation trial of the multigene diagnositic signature for the diagnosis of prostate cancer from nontumor-containing biopsy tissue.
Role: PI
1R01CA122558-01A2 Zi, Xiaolin (PI) 12/1/2007-11/30/2012
NIH/NCI
Chemoprevention of urinary bladder carcinogenesis by flavokawain A
Goals are to: (1) Determine flavokawain A’s ability to inhibit bladder tumor development and progression in a) UPII- mutant Ha-ras transgenic mice that produce superficial papillary TCC and b) UPII-SV40T transgenic mice that produce CIS with progression to high-grade superficial papillary and invasive tumors. (2) Determine flavokawain A’s efficacy in inhibiting bladder carcinogenesis in the OH-BBN-induced model of urinary bladder cancers in mice. (3) Investigate in vitro molecular mechanisms of flavokawain A leading to cell cycle arrests and apoptosis.
Role: Collaborator
Completed Research
UO1 CA152738-01 Mercola (PI) 07/1/10 – 06/30/15
NIH/NCI
The Prostate Cancer Tumor Microenvironment Exhibits Differentially Expressed Genes Useful for Diagnosis
The goal of this project is to develop a tissue resource and apply the tissue resource to a prospective clinical trial of the UCI SPECS Diagnositic Classifier for the diagnosis of prostate cancer using patient fresh frozen biopsy material for suspected prostate cancer cases where the initial biopsy used in the prospective study is ambiguous and a second biopsy is scheduled. The study will be evaluated by comparison of the prediciton made for the first biopsy to the clinical results observed for the second biopsy. Early detection will be evaluated by comparsion of the time of the first biopsy to the average time of second biopsies, usually 3 – 12 months. The functional role of the genes of the Diagnositic Classifier will be investigated by testing the hypothesis that paracrine factors of the tumor alter gene expression of tumor-adjacent but not distant stroma via the wnt and TGFberta1 regulated pathways.
Role: PI
BC050883 Mercola (PI) 4/1/06 – 3/31/10
Army Medical Research & Materiel Command $750,000
Novel Array-Based Target Identification for Synergistic Sensitization of Breast Cancer to Herceptin
BCTR65506 Mercola (PI) 9/1/06-8/31/09
Susan G. Komen Foundation -
Array-Based Identification of Genes Causing Chemotherapy Resistance by Breast Cancer
082-07 Mercola (PI) 8/1/07-7/31/09
Mary Kay Ash Foundation
Development of a Diagnostic Test for Breast Cancer Based on DNA Methylation Signature
2P30 CA-62203-14 Meyskens (PI) 8/1/02-1/31/09
NIH/NCI - University of California, Irvine
Cancer Center Support Grant
1 U01 CA114810-01 Mercola (PI) 07/01/05-06/30/11
NIH/NCI
Evaluation of Predictive Signatures of Prostate Cancer
A multi-disciplinary, multi-institutional consortium assembled to develop a predictive signature of prostate cancer and to validate the signature in a prospective trial.
Role: PI
2005-2605 FROM THE CANCER PROJECT Mercola (PI) 09/01/08-08/31/11
CANCER PROJECT OF WASHINGTON D.C.
Identification of gene transcript levels that correlated with diet of newly diagnosed prostate cancer patients
UCI SPECS consented patients are also recruited by informed consent to complete and electronic diet questionnaire at the time of diagnosis of prostate cancer and to provide blood used for analysis of analyte that confirm the veracity of diet survey results. The diet questionnaire results are analyzed by the Viorcare Inc./Fred Hutch Cancer Research Institute algorithm to determine over 250 dietary values which are then correlated with gene expression as measure by Affymetrix U133 plus 2.0 arrays of fresh frozen prostate cancer tissue of the same patients collected by the UCI SPECS project.
Role: PI
PHS 398/2590 (Rev. 06/09) Page Biographical Sketch Format Page